| Title |
Treatment of Cutaneous Lupus
|
|---|---|
| Published in |
Current Rheumatology Reports, April 2011
|
| DOI | 10.1007/s11926-011-0180-z |
| Pubmed ID | |
| Authors |
Aileen Y. Chang, Victoria P. Werth |
| Abstract |
Cutaneous lupus erythematosus (CLE) is an autoimmune inflammatory skin disease seen in patients with or without systemic lupus erythematosus. The management of CLE includes treatment and prevention of lesions as well as routine assessment for systemic disease. Treatment options include topical and systemic therapies. Topical therapies include corticosteroids and calcineurin inhibitors. Systemic therapies generally fall under one of three categories: antimalarials, immunomodulators (eg, dapsone and thalidomide), and immunosuppressives (eg, methotrexate and mycophenolate). Evidence for the treatment of CLE has been limited by few prospective studies and the lack of a validated outcome measure (until recently). There is good evidence to support the use of topical steroids and calcineurin inhibitors, although most of these trials have not used placebo or vehicle controls. There have been no randomized, placebo-controlled trials evaluating systemic therapies in the treatment of CLE. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Uruguay | 1 | 1% |
| Italy | 1 | 1% |
| Unknown | 72 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 15 | 20% |
| Researcher | 6 | 8% |
| Student > Master | 5 | 7% |
| Student > Doctoral Student | 5 | 7% |
| Professor | 5 | 7% |
| Other | 18 | 24% |
| Unknown | 20 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 53% |
| Agricultural and Biological Sciences | 2 | 3% |
| Unspecified | 2 | 3% |
| Computer Science | 1 | 1% |
| Economics, Econometrics and Finance | 1 | 1% |
| Other | 8 | 11% |
| Unknown | 21 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2018.
All research outputs
#5,954,154
of 22,655,397 outputs
Outputs from Current Rheumatology Reports
#204
of 706 outputs
Outputs of similar age
#33,283
of 109,024 outputs
Outputs of similar age from Current Rheumatology Reports
#2
of 4 outputs
Altmetric has tracked 22,655,397 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 706 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,024 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.